These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12192162)

  • 1. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.
    van Rossum AM; Bergshoeff AS; Fraaij PL; Hugen PW; Hartwig NG; Geelen SP; Wolfs TF; Weemaes CM; De Groot R; Burger DM
    Pediatr Infect Dis J; 2002 Aug; 21(8):743-7. PubMed ID: 12192162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
    Goujard C; Legrand M; Panhard X; Diquet B; Duval X; Peytavin G; Vincent I; Katlama C; Leport C; Bonnet B; Salmon-Céron D; Mentré F; Taburet AM;
    Clin Pharmacokinet; 2005; 44(12):1267-78. PubMed ID: 16372824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in durability of treatment with initial PI-based regimens.
    Pérez-Elías MJ; Moreno A; Moreno S; Antela A; Dronda F; Muñoz V; Casado JL; Quereda C; Lopez D; Navas E
    HIV Clin Trials; 2003; 4(6):391-9. PubMed ID: 14628282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
    Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
    HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial.
    Gibb DM; Goodall RL; Giacomet V; McGee L; Compagnucci A; Lyall H;
    Pediatr Infect Dis J; 2003 Jan; 22(1):56-62. PubMed ID: 12544410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.
    Burger D; Hugen P; Reiss P; Gyssens I; Schneider M; Kroon F; Schreij G; Brinkman K; Richter C; Prins J; Aarnoutse R; Lange J;
    AIDS; 2003 May; 17(8):1157-65. PubMed ID: 12819517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.
    Le Moing V; Peytavin G; Journot V; Cottalorda J; Bouvet E; Chêne G; Préau M; de Boever CM; Leport C; Raffi F;
    J Acquir Immune Defic Syndr; 2003 Dec; 34(5):497-9. PubMed ID: 14657760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
    Duval X; Peytavin G; Albert I; Bénoliel S; Ecobichon JL; Brun-Vézinet F; Mentré F; Leport C; Vildé JL
    HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
    Riddler SA; Havlir D; Squires KE; Kerr B; Lewis RH; Yeh K; Wynne LH; Zhong L; Peng Y; Deutsch P; Saah A
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3877-82. PubMed ID: 12435691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and antiviral effect of protease inhibitors in children.
    Temple ME; Koranyi KI; Nahata MC
    Pharmacotherapy; 2001 Mar; 21(3):287-94. PubMed ID: 11253853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy.
    Urban AW; Bean P; Aziz D; Graziano FM; Neudeck BL
    Int J STD AIDS; 2003 Feb; 14(2):103-8. PubMed ID: 12662388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.
    Duval X; Mentré F; Lamotte C; Chêne G; Spire B; Dellamonica P; Panhard X; Salmon D; Raffi F; Peytavin G; Leport C;
    Ther Drug Monit; 2005 Feb; 27(1):63-70. PubMed ID: 15665749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.
    Fischl MA; Ribaudo HJ; Collier AC; Erice A; Giuliano M; Dehlinger M; Eron JJ; Saag MS; Hammer SM; Vella S; Morse GD; Feinberg JE; Demeter LM; Eshleman SH;
    J Infect Dis; 2003 Sep; 188(5):625-34. PubMed ID: 12934177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indinavir, nelfinavir -- twice a day?
    TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.
    Sension MG; Bellos NC; Johnson J; Sepulveda GE; DeJesus E; Santana JL; Ames MH; Goodwin SD
    HIV Clin Trials; 2002; 3(5):361-70. PubMed ID: 12407485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.
    Yerly S; Rickenbach M; Popescu M; Taffe P; Craig C; Perrin L;
    Antivir Ther; 2001 Sep; 6(3):185-9. PubMed ID: 11808753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1.
    van Rossum AM; Geelen SP; Hartwig NG; Wolfs TF; Weemaes CM; Scherpbier HJ; van Lochem EG; Hop WC; Schutten M; Osterhaus AD; Burger DM; de Groot R
    Clin Infect Dis; 2002 Apr; 34(7):1008-16. PubMed ID: 11880968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.